FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739
This study is recruiting at 41 US sites in 21 states, according to its ClinicalTrials.gov record last updated .
Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Urinary Bladder Neoplasms
- Neoplasm Metastasis
- Ureteral Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- August 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- University of Arizona - Cancer Center · Tucson, AZ
California · 5
- City of Hope · Duarte, CA
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology · Los Angeles, CA
- University of California - Irvine · Orange, CA
- University of California (UC) Davis Comprehensive Cancer Center · Sacramento, CA
- Stanford Medicine Cancer Center · Stanford, CA
Florida · 1
- Advent Health · Orlando, FL
Georgia · 1
- Emory University Hospital · Atlanta, GA
Illinois · 1
- The University of Chicago Medical Center (UCMC) · Chicago, IL
Indiana · 1
- Indiana University (IU) Melvin and Bren Simon Cancer Center · Indianapolis, IN
Louisiana · 2
- Mary Bird Perkins Cancer Center · Baton Rouge, LA
- Ochsner Clinic Foundation · New Orleans, LA
Maryland · 1
- Johns Hopkins Kimmel Cancer Center · Baltimore, MD
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- Barbara Ann Karmanos Cancer Institute · Detroit, MI
Missouri · 1
- Washington University in St. Louis · St Louis, MO
New York · 7
- Columbia University · New York, NY
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, NY
- Icahn School of Medicine at Mount Sinai · New York, NY
- New York University (NYU) · New York, NY
- Weill Cornell Medicine · New York, NY
- University of Rochester - Wilmot Cancer Institute · Rochester, NY
- Montefiore Medical Center · The Bronx, NY
North Carolina · 1
- University of North Carolina (UNC) - Chapel Hill · Chapel Hill, NC
Ohio · 2
- University of Cincinnati Medical Center (UCMC) · Cincinnati, OH
- The Ohio State University (OSU) · Columbus, OH
Oklahoma · 1
- University of Oklahoma - Health Sciences Center · Oklahoma City, OK
Pennsylvania · 5
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute · Lancaster, PA
- Thomas Jefferson University · Philadelphia, PA
- University of Pennsylvania · Philadelphia, PA
- Allegheny General Hospital · Pittsburgh, PA
- University of Pittsburgh Medical Center · Pittsburgh, PA
South Carolina · 1
- Carolina Urologic Research Center · Myrtle Beach, SC
Tennessee · 3
- Sarah Cannon and HCA Research Institute · Nashville, TN
- Tennessee Oncology · Nashville, TN
- Vanderbilt University Medical Center · Nashville, TN
Texas · 3
- Texas Oncology, P.A · Dallas, TX
- University of Texas Southwestern · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
Utah · 1
- University of Utah · Salt Lake City, UT
Vermont · 1
- University of Vermont Medical Center · Burlington, VT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.